Table 2 Representing the exosomal miRNAs in biological fluids as prognostic and diagnostic biomarkers and therapeutic targets in breast cancer
From: Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer
Exosomal miRNA | Sample Type | Role | Mechanism of action | Reference |
|---|---|---|---|---|
miR-148a | Serum | Prognosis | Tumor-node-metastasis (TNM) stage, differentiation, and lymph node metastasis | Li et al. (2020) [46] |
miR-138-5p | Serum | Prognosis | modulates polarization of tumor-associated macrophages | Xun et al. (2021) [47] |
miR-363-5p | Plasma | Prognostic | inhibits lymph node metastasis by downregulating PDGFB | Wang X et al. (2021) [48] |
miR-1910-3p | Serum | Diagnostic | promotes proliferation, metastasis, and autophagy of breast cancer cells | Wang B et al. (2020) [49] |
miR-17-5p | Serum | Diagnostic | Predicted target genes | Lv et al. (2020) |
miR-423, miR-424, let7-i and miR-660 | Urine | Diagnostic | Tumor suppressor effect | Hirschfeld et al. (2020) [45] |
miR-21-5p | Plasma | Diagnostic | Tumor suppressor effect | Liu et al. (2021) [51] |
miR-146a, miR-1290 and miR-3662 | Serum | Diagnostic | monitor patient condition in the course of surgery and chemotherapy. | Li et al. (2021) [52] |
miR-567 | Tissue and serum | Therapeutic target | Reversing trastuzumab resistance via regulating autophagy | Han et al. (2020) [53] |
miR-9 and miR-181a | Blood | Therapeutic target | promoted the expansion of eMDSCs | Jiang et al. (2020) [54] |
miR-7641 | Plasma | Therapeutic target | promotes breast cancer progression and metastasis | Shen et al. (2021) [55] |